Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 489 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Not listed Not applicable Interventional

Sebacia Postmarket Study of Real-World Use

NCT03818555
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles Treatment
Other
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Murfreesboro, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Results available

MLE4901 vs. Placebo for the Treatment of PCOS

NCT02865915
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
MLE4901, Placebo
Drug
Lead sponsor
Millendo Therapeutics US, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Oceanside, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars

NCT02103127
View directory record Official record
Conditions
Acne Scars
Interventions
755nm Alexandrite laser with lens array
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

NCT00031096
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Mobile, Alabama • Boulder, Colorado • Newnan, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of S6G5T3 in the Treatment of Acne Vulgaris

NCT03761810
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

NCT03761784
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

NCT05704114
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change, Erythema, Skin Scarring
Interventions
Tazarotene 0.045% Lotion
Drug
Lead sponsor
Dr. Emmy Graber
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Straberi Microneedling For Atrophic Acne

NCT04740268
View directory record Official record
Conditions
Atrophic Acne Scar
Interventions
Straberi
Device
Lead sponsor
Universal Skincare Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

NCT04179175
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Rogers, Arkansas • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Results available

Preoperative Jumpstart for Decolonization of P. Acnes

NCT03466658
View directory record Official record
Conditions
Shoulder Arthropathy Associated With Other Conditions
Interventions
JumpStart Antimicrobial Wound Dressing
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional Results available

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

NCT05608499
View directory record Official record
Conditions
Acne Keloidalis Nuchae, AKN
Interventions
Duobrii, Placebo, Bryhali
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Profiling the Skin Microbiome in Response to Altreno in Acne Patients

NCT04548349
View directory record Official record
Conditions
Acne, Healthy
Interventions
Altreno, Benzoyl peroxide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
25
States / cities
Hoover, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Results available

Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne

NCT01629797
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Educational script on Acne
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment

NCT03430921
View directory record Official record
Conditions
Scarring, Acne
Interventions
Enlighten™ Laser and a MLA Attachment
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Early Phase 1 Interventional

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

NCT04979520
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Brodalumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional Results available

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

NCT02189629
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene)
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Mobile, Alabama • Rogers, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

NCT04163263
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
BOS-356, Vehicle
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Fremont, California • Sanford, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Completed No phase listed Observational

Cultural Differences in Treatment Preferences and Perceptions of Acne

NCT03192163
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Survey
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

NCT02218034
View directory record Official record
Conditions
Acne Vulgaris
Interventions
AGN-190168 Formulation 1, AGN-190168 Formulation 2, tazarotene gel 0.1%, tazarotene cream 0.1%
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Results available

BPO vs Hibiclens Soap for Surgical Preparation

NCT04021524
View directory record Official record
Conditions
Propionibacterium Acnes
Interventions
Benzoyl Peroxide 10% Bar, Chlorhexidine Gluconate
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 20, 2026, 5:30 PM EDT